Release Summary

Alexion announced that researchers presented new two-year data from an ongoing, open-label Phase 2/3 trial of Kanuma™ (sebelipase alfa) in infants with lysosomal acid lipase deficiency (LAL-D).

Alexion Pharmaceuticals, Inc.